Prolacta's Human Milk-Based Fortifiers Receive World's First Prescription Drug Status in Japan Following JASMINE Trial Success

Key Takeaways

• Japan’s Ministry of Health grants Prolacta’s human milk-based fortifiers prescription drug status - a global first in neonatal care
• JASMINE trial shows superior growth outcomes in premature infants while maintaining Japan’s renowned low necrotizing enterocolitis rates
• Breakthrough provides safer alternative to delayed cow milk-based fortification practices and sets regulatory precedent for worldwide expansion

---

Prolacta Bioscience has achieved a groundbreaking regulatory milestone as Japan’s Ministry of Health, Labour, and Welfare granted prescription drug status to the company’s human milk-based fortifiers for premature infants - marking the first time any neonatal fortifier has received such designation globally.

The approval follows successful results from the landmark JASMINE clinical trial, published in the Journal of Perinatology, which demonstrated that Prolacta’s human milk-based fortifiers deliver superior growth outcomes in premature infants while preserving Japan’s exceptionally low necrotizing enterocolitis (NEC) rates.

Clinical Trial Results Transform Neonatal Care Standards

The JASMINE trial addressed a critical challenge in Japanese neonatal intensive care units, where medical professionals often delay introducing cow milk-based fortifiers to avoid complications, potentially compromising infant growth. Prolacta’s human milk-based alternative proved both safe and effective, enabling earlier nutritional intervention without increasing NEC risk.

“Better growth has been associated with improved long-term neurodevelopment,” according to the study findings, highlighting the broader implications beyond immediate nutritional benefits. The trial results suggest that premature infants receiving human milk-based fortification may experience enhanced developmental outcomes throughout their lives.

Regulatory Breakthrough Sets Global Precedent

Japan’s decision to grant prescription drug status represents a paradigm shift in how regulatory authorities view neonatal nutrition products. This classification elevates human milk-based fortifiers from nutritional supplements to recognized medical treatments, potentially influencing regulatory frameworks worldwide.

The prescription drug designation provides several advantages, including enhanced quality controls, standardized dosing protocols, and improved healthcare provider confidence in prescribing these specialized products for vulnerable premature infant populations.

Market Impact and Competitive Landscape

This regulatory success positions Prolacta advantageously against traditional cow milk-based fortifiers, which dominate the current neonatal nutrition market. The company’s human milk-based approach addresses safety concerns that have led to conservative fortification practices in Japan and other markets prioritizing NEC prevention.

The JASMINE trial data could serve as a foundation for regulatory submissions in other countries, potentially accelerating global market access for Prolacta’s products. Healthcare systems worldwide grapple with similar challenges balancing nutritional adequacy and safety in premature infant care.

Long-term Implications for Neonatal Medicine

The connection between improved growth and enhanced neurodevelopment outcomes carries significant implications for healthcare policy and clinical practice. Premature infants who receive optimal nutrition during critical early development periods may require fewer long-term interventions and achieve better quality of life outcomes.

Japan’s regulatory decision may encourage other health authorities to reconsider their approaches to neonatal nutrition regulation, potentially leading to more rigorous evaluation standards and improved treatment options for premature infants globally.

Future Outlook and Expansion Opportunities

Prolacta’s success in Japan establishes a regulatory template for international expansion. The company can leverage JASMINE trial data and Japan’s prescription drug designation to support applications in other markets, potentially accelerating adoption of human milk-based fortification protocols worldwide.

This breakthrough also validates the scientific approach of using human milk components for premature infant nutrition, potentially spurring additional research and development in this specialized therapeutic area.

---

Frequently Asked Questions

What does prescription drug status mean for Prolacta’s human milk-based fortifiers?

Prescription drug status elevates these fortifiers from nutritional supplements to recognized medical treatments, providing enhanced quality controls, standardized protocols, and increased healthcare provider confidence in treating premature infants.

When will these human milk-based fortifiers be available to patients in Japan?

The fortifiers have received prescription drug status from Japan’s Ministry of Health, Labour, and Welfare, making them available for prescription to premature infants requiring nutritional fortification in Japanese healthcare facilities.

How do human milk-based fortifiers compare to traditional cow milk-based alternatives?

The JASMINE trial showed human milk-based fortifiers provide superior growth outcomes while maintaining low necrotizing enterocolitis rates, offering a safer alternative to cow milk-based products that Japanese practitioners often delay using due to complication risks.

Related coverage

• NMPA Drug Approvals Surge in 2025: Record 61 First Global Approvals Signal Accelerated Market Access
• Drug Discovery Technology Market Size Tops USD 80.27 Billion by 2035
• TGA Australia drug approval pharmaceutical: what the regulator is